With the current sources of US supply chains being more diversified than before, China’s share in US goods imports is declining while Mexico becomes the largest exporter to the US market in 2023. However, can Mexico use this trade diversion to successfully outweigh China in US supply chains? This paper thus investigates whether the Mexico manufacturing sector is competitive enough to completely replace its Chinese counterparts and rise to a strategically vital supplier for the US economy. Based on multiple empirical evidence, we find that although US supply chain sources are shifting from China to Mexico, the major part of the value added of Mexican exports to the US market is generated in China. Moreover, our evidence shows that Mexico’s exports to the US concentrate on low-skill sectors, while China’s mainly consists of high-skill goods. Further discussion shows that the current US trade shift is highly likely due to China’s FDI inflows to Mexico’s traditionally strong export sector, motor vehicles. However, this shift is not significant enough for Mexico to become a capable substitute for China in the US supply chains. We conclude that the "trade diversion" strategy alone cannot support Mexico’s role in reducing the US supply chain dependence on China. Therefore, the US should better consider how to establish a sustainable trade framework that fosters stable cooperation with China.

This review aimed to analyze some problems and challenges that emerged from the COVID-19 pandemic since it has affected all global business sectors. During the pandemic, remote work was increased in response to social distance requirements to decrease the transmission of disease. In addition, increased delegation, teamwork, supply chains, sales activities, and business operations have all been disrupted. Many challenges have emerged in the management of organizations due to the pandemic including the lack of direct contact as the lockdown made many people work from home and placed restrictions on movement and travel and uncertainty about the future. The healthcare system was also affected by the COVID-19 pandemic and faced several difficulties including increased demand for medical supplies and personal protective equipment, a greater need for nurses and other skilled healthcare professionals, and increased pressure on healthcare facilities, emergency services, and critical care departments. These challenges have created some opportunities in the management systems of healthcare organizations and other sectors. It is recommended for leaders prepare and continuously work proactively to be ready for unexpected future crises. Risk management and planning for any unexpected situation are among the very important aspects of organizational management.

Pharmaceutical supply chains are critical to ensuring the availability of safe and effective medications, yet they face numerous challenges that can jeopardize public health. This article provides a comprehensive analysis of the key issues impacting pharmaceutical supply chains, including regulatory compliance, demand forecasting, supply chain visibility, quality assurance, and geopolitical risks. Regulatory compliance remains a significant concern due to the stringent guidelines imposed by authorities such as the FDA and EMA, which can lead to increased operational costs and time delays. Additionally, traditional demand forecasting methods often fail to accurately predict fluctuations in drug demand, resulting in stockouts or excess inventory. Limited supply chain visibility further complicates these challenges, hindering timely decision-making and operational efficiency. Quality assurance is paramount, as maintaining the integrity of pharmaceutical products throughout the supply chain is crucial to preventing costly recalls and ensuring patient safety. Moreover, the globalization of supply chains introduces vulnerabilities to geopolitical risks, trade disputes, and natural disasters. In response to these issues, this article outlines strategic recommendations for optimizing pharmaceutical supply chains. These include leveraging advanced analytics and IoT technologies to enhance demand forecasting and visibility, strengthening compliance through automated systems and training, fostering collaboration among stakeholders, implementing robust risk management frameworks, and investing in quality management systems. By adopting these strategies, pharmaceutical companies can enhance the efficiency and resilience of their supply chains, ultimately ensuring the continuous availability of essential medications for patients worldwide. This analysis serves as a critical resource for industry professionals seeking to navigate the complexities of pharmaceutical supply chains in an increasingly dynamic global environment.

The operational performance of Active Pharmaceutical Ingredients (API) supply chains often suffers from significant disruptions attributed to inherent vulnerabilities. Despite theoretical discussions, empirical evidence validating these vulnerabilities remains sparse. This study endeavours to empirically substantiate the vulnerabilities arising from dynamic disruptions within the pharmaceutical supply chain. Its primary goal is to discern actionable insights that can inform the development of robust resilience strategies capable of effectively mitigating such disruptions. This study investigates vulnerabilities within the active pharmaceutical ingredient (API) supply chain in response to disruptions. Despite theoretical insights, empirical evidence validating these vulnerabilities remains limited. Through empirical analysis, this research aims to identify and elucidate the specific vulnerabilities exacerbated by dynamic disruptions in the API supply chain. The findings are intended to inform the development of resilient strategies capable of mitigating the impact of disruptions on pharmaceutical supply chains.